Processa Pharmaceuticals, Inc.
PCSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,662 | $2,447 | $1,589 | $1,712 |
| G&A Expenses | $1,827 | $1,503 | $1,258 | $1,022 |
| SG&A Expenses | $1,827 | $1,503 | $1,258 | $1,022 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,489 | $3,951 | $2,847 | $2,735 |
| Operating Income | -$3,489 | -$3,951 | -$2,847 | -$2,735 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $52 | $17 | $13 | $6 |
| Pre-Tax Income | -$3,437 | -$3,934 | -$2,834 | -$2,729 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,437 | -$3,934 | -$2,834 | -$2,729 |
| % Margin | – | – | – | – |
| EPS | -1.75 | -6.25 | -7,438 | -19.5 |
| % Growth | 72% | 99.9% | -38,043.6% | – |
| EPS Diluted | -1.75 | -6.25 | -7,438 | -19.5 |
| Weighted Avg Shares Out | 1,901 | 623 | 381 | 148 |
| Weighted Avg Shares Out Dil | 1,901 | 623 | 381 | 148 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $17 | $13 | $6 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3,436 | -$3,950 | -$2,847 | -$2,734 |
| % Margin | – | – | – | – |